Senda Ajroud-Driss

Grants

Grants per year 1999 2020 2021 2025

• 25 Finished
• 37 Active

Grants per year

Search results

• Active

  Cure SMA Care Center Network and Clinical Data Registry

  Ajroud-Driss, S.

  Families of Spinal Muscular Atrophy

  6/1/22 → 5/31/23

  Project: Research project

  • Data transfer 100%
  • Health 72%

• Prot#16970: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SAR443820 in Adult Participants with Amyotrophic Lateral Sclerosis, Followed by an Open-Label Extension

  Ajroud-Driss, S.

  Sanofi US Services Inc.

  3/29/22 → 3/29/25

  Project: Research project

• Prot#WP-0512-003: A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients with Amyotrophic Lateral Sclerosis (ALS)

  Ajroud-Driss, S.

  DP Clinical, Inc., Woolsey Pharmaceuticals, Inc.

  3/3/22 → 3/22/25

  Project: Research project

• HEALEY ALS Platform Trial Regimen-Specific Appendix (RSA) E to Master Protocol TREHALOSE S-005

  Ajroud-Driss, S.

  Massachusetts General Hospital, NexMed, Inc.

  3/1/22 → 12/4/24

  Project: Research project

• Protocol Number: A35-004 - Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS)

  Ajroud-Driss, S.

  Julius Clinical Research B.V, Amylyx Pharmaceuticals, Inc.

  1/12/22 → 1/12/25

  Project: Research project

• UMMS-ASO-STMN2 Study

  Ajroud-Driss, S.

  Hopewell Fund

  11/1/21 → 10/31/22

  Project: Research project

• I AM ALS: Expanded Access Protocol (EAP) Program Proposal

  Ajroud-Driss, S.

  Massachusetts General Hospital, I AM ALS

  9/3/21 → 12/31/22

  Project: Research project

• Prot #233AS303: A Phase 3 Randomized, Placebo-Controlled Trial With a Longitudinal Natural History Run-In and Open-Label Extension to Evaluate BIIB067 Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation

  Ajroud-Driss, S.

  DrugDev Inc., Biogen MA Inc.

  8/12/21 → 8/12/24

  Project: Research project

• Prot #BASICHR0053: Evaluation of digital technologies for home-based assessment of ALS patients

  Ajroud-Driss, S.

  Novartis Pharmaceuticals Corporation

  8/3/21 → 11/30/22

  Project: Research project

• Prot# VMALS-002-2: A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety of Engensis in Participants with Amyotrophic Lateral Sclerosis

  Ajroud-Driss, S.

  Worldwide Clinical Trials, Inc., ViroMed Co., Ltd.

  4/29/21 → 4/29/24

  Project: Research project

• Prot# MT-1186-A02: A Phase 3b, Multicenter, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Oral Edaravone Administered for a Period of 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)

  Ajroud-Driss, S.

  ICON Clinical Research, LLC, Mitsubishi Tanabe Pharma America, Inc.

  3/16/21 → 3/16/24

  Project: Research project

• HEALEY ALS Platform Trial Regimen-Specific Appendix (RSA) A to Master Protocol ZILUCOPLAN | Home Spirometry and Open-Label Extension (OLE) Period

  Ajroud-Driss, S.

  Massachusetts General Hospital, Ra Pharmaceuticals, Inc.

  3/15/21 → 3/14/23

  Project: Research project

• HEALEY ALS Platform Trial Regimen-Specific Appendix (RSA) C to Master Protocol CNM-Au8 | Home Spirometry and Open-Label Extension (OLE) Period

  Ajroud-Driss, S.

  Massachusetts General Hospital, Clene Nanomedicine, Inc.

  3/15/21 → 3/14/23

  Project: Research project

• HEALEY ALS Platform Trial Regimen-Specific Appendix (RSA) B to Master Protocol Verdiperstat | Home Spirometry and Open-Label Extension (OLE) Period

  Ajroud-Driss, S.

  Massachusetts General Hospital, Biohaven Pharmaceuticals, Inc.

  3/15/21 → 3/14/23

  Project: Research project

• Prot#AB19001: A Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib in Combination with Riluzole Versus Placebo in Combination with Riluzole in the Treatmen

  Ajroud-Driss, S.

  AB Science

  2/26/21 → 2/26/24

  Project: Research project

• Prot# 233AS102: An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults with Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 M

  Ajroud-Driss, S.

  Quintiles, Inc., Biogen MA Inc.

  11/24/20 → 11/24/23

  Project: Research project

• HEALEY ALS Platform Trial Regimen-Specific Appendix (RSA) D to Master Protocol Pridopidine | Double-Blind Phase

  Ajroud-Driss, S.

  Massachusetts General Hospital

  11/20/20 → 11/19/22

  Project: Research project

• Prot #233AS101: A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB067 Administered to Adult Subjects with Amyotrophic Lateral Sclerosis and Confirmed Superoxide Dismutase 1 Mutation

  Ajroud-Driss, S.

  Quintiles, Inc., Biogen MA Inc.

  9/9/20 → 9/9/23

  Project: Research project

• HEALEY ALS Platform Trial Regimen-Specific Appendix (RSA) D to Master Protocol PRIDOPIDINE | Home Spirometry and Open-Label Extension (OLE) Period

  Ajroud-Driss, S.

  Massachusetts General Hospital, Prilenia Neurotherapeutics Ltd

  9/4/20 → 3/14/23

  Project: Research project

• Oxidative Markers and Efficacy in ALS/MND Phenotypes Treated with Edaravone: Proof of Concept

  Ajroud-Driss, S.

  Loma Linda University, Mitsubishi Tanabe Pharma America, Inc.

  9/2/20 → 9/2/23

  Project: Research project

• Radicava®/(Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)

  Ajroud-Driss, S.

  Massachusetts General Hospital, Mitsubishi Tanabe Pharma America, Inc.

  8/3/20 → 8/3/23

  Project: Research project

• PLS Natural History Study

  Ajroud-Driss, S.

  Columbia University, Spastic Paraplegia Foundation, Inc.

  7/15/20 → 7/14/22

  Project: Research project

  • Urine Specimen Collection 100%
  • Natural History 59%
  • Congresses 58%
  • Urine 14%
  • Interviews 13%

• Emerging Real-World Use of Nusinersen in Adult Patients with Spinal Muscular Atrophy (SMA) in the US: A Multi-Site Chart Review Study

  Ajroud-Driss, S.

  Analytica La-Ser International, Inc., Biogen Inc.

  7/6/20 → 7/6/23

  Project: Research project

• Prot #ALN-TTR02-012: A Phase 4 Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients with Polyneuropathy of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with a V122I or T60A Mutation

  Ajroud-Driss, S.

  Quintiles, Inc., Alnylam Pharmaceuticals, Inc.

  6/29/20 → 6/29/23

  Project: Research project

• Prot#US-SPN-17-11267: A Prospective, Multi-center, Open-Label, Observational Study of the Safety, Tolerability and Effectiveness of SPINRAZA in Adults with SMA

  Ajroud-Driss, S.

  Washington University St. Louis, Biogen Inc.

  5/14/20 → 5/14/23

  Project: Research project